Programmed death protein 1 (PD1) is a common immunosuppressive member on the
surface of T cells and plays an imperative part in downregulating the immune system and …

Cancer immunotherapies have changed the landscape of cancer treatment during the past
few decades. Among them, immune checkpoint inhibitors, which target PD-1, PD-L1 and …

PURPOSE To increase awareness, outline strategies, and offer guidance on the
recommended management of immune-related adverse events (irAEs) in patients treated …

Aims This observational study characterized cardiovascular disease (CVD) mortality risk for
multiple cancer sites, with respect to the following:(i) continuous calendar year,(ii) age at …

Abstract Immune-checkpoint inhibitors (ICIs), including anti-cytotoxic T lymphocyte antigen 4
(CTLA-4), anti-programmed cell death 1 (PD-1) and anti-programmed cell death 1 ligand 1 …

Less than a year after the global emergence of the coronavirus SARS-CoV-2, a novel
vaccine platform based on mRNA technology was introduced to the market. Globally, around …

Background: Myocarditis is an uncommon, but potentially fatal, toxicity of immune checkpoint
inhibitors (ICI). Myocarditis after ICI has not been well characterized. Objectives: The authors …

Cancer immunotherapy has transformed the treatment of cancer. However, increasing use of
immune-based therapies, including the widely used class of agents known as immune …

Purpose To increase awareness, outline strategies, and offer guidance on the
recommended management of immune-related adverse events in patients treated with …

The NCCN Guidelines for Management of Immunotherapy-Related Toxicities provide
interdisciplinary guidance on the management of immune-related adverse events (irAEs) …